Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

Trial Profile

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NC-318 (Primary)
  • Indications Breast cancer; Carcinoma; Colorectal cancer; Endometrial cancer; Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors NextCure
  • Most Recent Events

    • 11 Nov 2019 Planned number of patients changed from 110 to 143.
    • 09 Nov 2019 According to an NextCure media release, Phase II portion of this trial has been initiated and company expects to report initial data from the Phase II portion by the end of 2020.
    • 09 Nov 2019 According to an NextCure media release, updated results from Phase I portion of this trial were presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top